Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brincidofovir - Chimerix

Drug Profile

Brincidofovir - Chimerix

Alternative Names: BCV; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix

Latest Information Update: 18 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Centers for Disease Control and Prevention; Chimerix; National Institutes of Health (USA); University of Oxford
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Cytomegalovirus infections; Adenovirus infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cytomegalovirus infections; Smallpox
  • Phase II/III Viral infections
  • Research Monkeypox
  • No development reported Human polyomavirus infections
  • Discontinued Adenovirus infections; Ebola virus infections

Most Recent Events

  • 05 Nov 2019 Chimerix plans to schedule a pre-NDA meeting with the US FDA for Smallpox in the first quarter of 2020
  • 30 Sep 2019 Brincidofovir - Chimerix is available for licensing as of 30 Sep 2019. https://www.symbiopharma.com/index_e.html
  • 30 Sep 2019 Chimerix and SymBio Pharmaceuticals enter into global licensing agreement to develop brincidofovir in all human indications except for smallpox
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top